Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Risdiplam (RO7034067) (RG7916) is orally administered. Risdiplam is a centrally and peripherally distributed SMN2 pre-mRNA splicing modifier which increases survival motor neuron (SMN) protein levels[1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 55.00 | |
2 mg | In stock | $ 81.00 | |
5 mg | In stock | $ 129.00 | |
10 mg | In stock | $ 211.00 | |
25 mg | In stock | $ 376.00 | |
50 mg | In stock | $ 559.00 | |
100 mg | In stock | $ 786.00 |
Description | Risdiplam (RO7034067) (RG7916) is orally administered. Risdiplam is a centrally and peripherally distributed SMN2 pre-mRNA splicing modifier which increases survival motor neuron (SMN) protein levels[1]. |
In vitro |
Risdiplam is a modifier of SMN2 splicing, leading to an increase in SMN2 full-length transcript and thus functional SMN protein. Risdiplam modulates SMN2 pre-mRNA splicing towards the production of full-length SMN2 mRNA and increases SMN protein levels [1]. Spinal muscular atrophy (SMA) type I remains the most common genetic disease resulting in death in infancy. Characterized by progressive motor and respiratory muscle weakness, this autosomal recessive neuromuscular disorder is caused by low levels of the survival motor neuron protein (SMN) due to inactivating bi-allelic deletions and other disabling mutations in the survival motor neuron 1 (SMN1) gene[1]. Risdiplam is a modifier of SMN2 splicing, leading to an increase in SMN2 full-length transcript and thus functional SMN protein. Risdiplam modulates SMN2 pre-mRNA splicing towards the production of full-length SMN2 mRNA and increases SMN protein levels [1]. Spinal muscular atrophy (SMA) type I remains the most common genetic disease resulting in death in infancy. Characterized by progressive motor and respiratory muscle weakness, this autosomal recessive neuromuscular disorder is caused by low levels of the survival motor neuron protein (SMN) due to inactivating bi-allelic deletions and other disabling mutations in the survival motor neuron 1 (SMN1) gene[1]. |
Synonyms | RO7034067, RG7916 |
Molecular Weight | 401.46 |
Formula | C22H23N7O |
CAS No. | 1825352-65-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 2 mg/mL (4.98 mM), Sonication is recommended.
Ethanol: 2 mg/mL (4.98 mM), Sonication is recommended.
H2O: 2.22 mg/mL (5.53 mM), when pH is adjusted to 6 with HCl. Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Risdiplam 1825352-65-5 Cell Cycle/Checkpoint DNA Damage/DNA Repair DNA/RNA Synthesis RG 7916 Inhibitor RO 7034067 RO7034067 RG-7916 RO-7034067 inhibit RG7916 inhibitor